Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: PSNL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.29
1 Year Target Price $11.29
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 735.30M USD | Price to earnings Ratio - | 1Y Target Price 11.29 |
Price to earnings Ratio - | 1Y Target Price 11.29 | ||
Volume (30-day avg) 7 | Beta 2.02 | 52 Weeks Range 2.83 - 11.50 | Updated Date 02/23/2026 |
52 Weeks Range 2.83 - 11.50 | Updated Date 02/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Earnings Date
Report Date 2026-02-19 | When - | Estimate -0.2788 | Actual - |
Profitability
Profit Margin -106.92% | Operating Margin (TTM) -160.68% |
Management Effectiveness
Return on Assets (TTM) -20.95% | Return on Equity (TTM) -43.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 625816001 | Price to Sales(TTM) 10.64 |
Enterprise Value 625816001 | Price to Sales(TTM) 10.64 | ||
Enterprise Value to Revenue 9.06 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88804348 | Shares Floating 52296881 |
Shares Outstanding 88804348 | Shares Floating 52296881 | ||
Percent Insiders 31.65 | Percent Institutions 75.21 |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. was founded in 2011 by Dr. Richard M. Shugarman and Dr. Michael J. Snyder. The company has evolved from a genomic sequencing and analysis provider to a clinical genomics company focused on enabling precision medicine. Key milestones include the development of its proprietary ACE technology platform, the launch of various clinical oncology tests, and partnerships with major pharmaceutical companies.
Core Business Areas
- Clinical Genomics: Personalis offers a suite of advanced genomic solutions for cancer, including tumor sequencing, liquid biopsy, and companion diagnostics. These services aim to provide actionable insights for personalized cancer treatment and drug development.
- Research Services: The company provides comprehensive genomic sequencing and bioinformatics analysis for academic and biopharmaceutical researchers, supporting various stages of drug discovery and development.
- Diagnostic Development: Personalis develops and commercializes novel genomic diagnostic tests designed to improve patient outcomes and facilitate precision medicine approaches.
Leadership and Structure
Personalis is led by a management team with extensive experience in genomics, biotechnology, and healthcare. The organizational structure is designed to support its core business segments and strategic partnerships.
Top Products and Market Share
Key Offerings
- NeXT Personalu00ae: A comprehensive genomic profiling test for solid tumors that aims to identify actionable mutations, microsatellite instability (MSI), and tumor mutational burden (TMB). Market share data for individual products is not publicly disclosed, but it competes in the broader clinical oncology testing market with companies like Foundation Medicine (FMI) and Guardant Health (GH).
- ACE Technology: Personalis's proprietary ACE (Accuracy, Completeness, and Exome) sequencing technology enhances the accuracy and completeness of genomic data, making it a foundational component of their diagnostic and research offerings. This technology underpins their competitive differentiation rather than being a standalone product with direct market share.
- Liquid Biopsy Solutions: Personalis offers liquid biopsy tests for cancer detection, monitoring, and treatment selection. Competitors include Guardant Health (GH), Exact Sciences (EXAS), and Natera (NTRA).
Market Dynamics
Industry Overview
The clinical genomics and precision medicine market is rapidly growing, driven by advancements in sequencing technology, increasing understanding of cancer biology, and the demand for personalized therapies. The market is characterized by innovation, significant investment, and increasing regulatory scrutiny.
Positioning
Personalis positions itself as a leader in advanced clinical genomics, leveraging its proprietary technology to deliver superior data accuracy and actionable insights. Its strengths lie in its technology platform, focus on oncology, and collaborations with pharmaceutical partners.
Total Addressable Market (TAM)
The global precision oncology market is projected to grow significantly, with estimates ranging in the tens of billions of dollars annually. Personalis targets a substantial portion of this market through its diagnostic and drug development services. Its positioning is strong within niche areas of advanced genomic profiling and companion diagnostics.
Upturn SWOT Analysis
Strengths
- Proprietary ACE technology for enhanced genomic data accuracy
- Strong focus on oncology and precision medicine
- Established partnerships with pharmaceutical companies
- Experienced leadership team
- Growing pipeline of diagnostic tests
Weaknesses
- Dependence on third-party payer reimbursement for diagnostic tests
- Competition from larger, more established players
- Need for significant investment in R&D and commercialization
- Brand awareness compared to some competitors
Opportunities
- Expansion into new therapeutic areas beyond oncology
- Growth in companion diagnostics market
- Increasing adoption of liquid biopsies
- Strategic acquisitions to broaden service offerings
- Leveraging AI and machine learning for genomic data interpretation
Threats
- Changes in healthcare policy and reimbursement landscapes
- Rapid technological advancements by competitors
- Emergence of novel diagnostic modalities
- Data security and privacy concerns
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Foundation Medicine, Inc. (FMI)
- Guardant Health, Inc. (GH)
- Thermo Fisher Scientific Inc. (TMO)
- Roche Holding AG (RHHBY)
Competitive Landscape
Personalis competes in a dynamic market with both specialized genomic companies and larger diversified healthcare corporations. Its competitive advantages lie in its proprietary technology, which offers high accuracy and depth of analysis, and its specialized focus on oncology. However, it faces challenges from larger competitors with broader portfolios and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Personalis has demonstrated consistent revenue growth over the past several years, indicative of market adoption of its services and products.
Future Projections: Analyst projections often forecast continued revenue growth driven by market expansion and new product launches. Profitability is a key area of focus for future projections, with expectations for improvement as the company scales and achieves greater cost efficiencies.
Recent Initiatives: Recent initiatives likely include the expansion of its sales force, development of new diagnostic assays, strategic partnerships with pharmaceutical companies, and further commercialization of its NeXT Personalu00ae platform.
Summary
Personalis Inc. is a growing clinical genomics company with strong technological capabilities in oncology. Its proprietary ACE technology offers a competitive edge in data accuracy, driving revenue growth through diagnostic and research services. However, the company faces challenges from well-funded competitors and the complexities of healthcare reimbursement. Future success hinges on continued innovation, strategic partnerships, and achieving profitability in a rapidly evolving market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations filings (e.g., 10-K, 10-Q)
- Financial news and analysis platforms
- Industry market research reports
- Company press releases and official website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.